dsm-firmenich Awards €250K for 5 Longevity Research Projects Targeting Asia Pacific Aging

For the biotech and pharma sector, dsm-firmenich's latest grant round is more than academic seed funding—it validates a translational pathway from nutritional science to clinical anti-aging products. The benchmark DO-HEALTH trial proved that a simple combination of omega-3, vitamin D, and exercise can exert measurable effects on biological aging, opening the door for a new class of nutraceutical and therapeutic agents. With €250,000 now directed at five Asia-Pacific research projects, the program accelerates the identification of region-specific bio-actives that could form the basis of future product pipelines, targeting the biology of aging itself.

dsm-firmenich has awarded its second Nutrition Research Grant to five projects, each receiving EUR50,000, to investigate the role of nutrients and bio-actives in promoting healthy longevity across the Asia Pacific region. The announcement was made at the 'Age Slower, Age Better: Advancing Healthy Longevity Across Asia Pacific' scientific symposium in Singapore on July 8, 2026. This round follows the inaugural 2024 grant focused on gut health and marks a significant escalation in the company's commitment to addressing the region's rapidly aging population—a demographic shift where, by 2050, one in four people will be over 60. With the average person now spending the last decade of life in ill health, the grant program directly targets the widening gap between lifespan and healthspan, aiming to translate nutritional science into practical interventions that can compress morbidity.

“

For the biotech and pharma sector, dsm-firmenich's latest grant round is more than academic seed funding—it validates a translational pathway from nutritional science to clinical anti-aging products.

The initiative comes at a time when the scientific understanding of aging is being transformed by landmark clinical evidence. Senior executives cited the DO-HEALTH study, Europe's largest clinical trial on healthy aging, which demonstrated that a regimen of algal omega-3 fatty acids, vitamin D, and a simple home exercise program could slow biological aging by up to 3.8 months over a three-year period. This finding provides a robust foundation for exploring how specific bio-actives can modulate the pathways of aging, from inflammaging and mitochondrial decline to epigenetic alterations. By funding research specifically in Asia Pacific populations, dsm-firmenich acknowledges that genetic, dietary, and cultural factors necessitate regionally tailored nutrition solutions—a principle they term 'Asia-for-Asia.' The record number of applications for this year's grant reflects the surging interest among academic and industry researchers in the nutraceutical and pharma sectors to develop evidence-based anti-aging products.

For the biotech and pharmaceutical industries, the grant represents more than a charitable act; it signals a strategic pivot toward preventive health and the growing market for science-backed functional foods, supplements, and potentially new therapeutic entities. Nutritional interventions that target aging biology sit at the intersection of food and pharma, presenting opportunities for companies like dsm-firmenich to lead in the emerging healthy longevity market. The projects selected, though not detailed in the initial release, likely range from preclinical studies to early clinical trials, generating data that could support future product claims or even regulatory nods for health claims. This blurring of lines between nutrition and medicine could accelerate the development of products that delay age-related diseases such as sarcopenia, cognitive decline, and cardiovascular conditions—all of which impose enormous healthcare costs.